1
|
Nehoff HL, Melton I, Crozier IG. A case report of a rare complication of an iatrogenic ventricular septal defect secondary to radiofrequency ablation. HeartRhythm Case Rep 2023; 9:542-544. [PMID: 37614390 PMCID: PMC10444561 DOI: 10.1016/j.hrcr.2023.05.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/25/2023] Open
Affiliation(s)
- Hayley L. Nehoff
- Department of Cardiology, Christchurch Public Hospital, Christchurch, New Zealand
| | | | - Ian G. Crozier
- Department of Cardiology, Christchurch Public Hospital, Christchurch, New Zealand
| |
Collapse
|
2
|
Affiliation(s)
- David L Jardine
- Department of Medicine, Christchurch School of Medicine, University of Otago, Christchurch, New Zealand; Department of General Medicine.
| | - Philip Adamson
- Department of Medicine, Christchurch School of Medicine, University of Otago, Christchurch, New Zealand; Department of Cardiology, Christchurch Hospital, Canterbury District Hospital Board, Christchurch, New Zealand
| | - Ian G Crozier
- Department of Cardiology, Christchurch Hospital, Canterbury District Hospital Board, Christchurch, New Zealand
| |
Collapse
|
3
|
Reddy VY, Al-Ahmad A, Aidietis A, Daly M, Melton I, Hu Y, Sulkin M, Rackauskas G, Ebner A, Hooks DA, Sofi A, Neužil P, Crozier IG. A Novel Visually Guided Radiofrequency Balloon Ablation Catheter for Pulmonary Vein Isolation: One-Year Outcomes of the Multicenter AF-FICIENT I Trial. Circ Arrhythm Electrophysiol 2021; 14:e009308. [PMID: 34583521 DOI: 10.1161/circep.120.009308] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
[Figure: see text].
Collapse
Affiliation(s)
- Vivek Y Reddy
- Department of Cardiology, Homolka Hospital, Prague, Czechia (V.Y.R., P.N.).,Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, NY (V.Y.R., A.S.)
| | - Amin Al-Ahmad
- Texas Cardiac Arrhythmia Institute at St. David's Medical Center, Austin (A.A.-A.)
| | - Audrius Aidietis
- Centre for Cardiology and Angiology, Vilnius University, Lithuania (A.A., G.R.)
| | - Matthew Daly
- Department of Cardiology, Christchurch Hospital, New Zealand (M.D., I.M., I.G.C.)
| | - Iain Melton
- Department of Cardiology, Christchurch Hospital, New Zealand (M.D., I.M., I.G.C.)
| | - Yan Hu
- Boston Scientific Corp., Electrophysiology, St. Paul, MN (Y.H., M.S.)
| | - Matthew Sulkin
- Boston Scientific Corp., Electrophysiology, St. Paul, MN (Y.H., M.S.)
| | | | - Adrian Ebner
- Cardiovascular Department, Sanatorio Italiano, Asunción, Paraguay (A.E.)
| | - Darren A Hooks
- Department of Cardiology, Wellington Hospital, New Zealand (D.A.H.)
| | - Aamir Sofi
- Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, NY (V.Y.R., A.S.)
| | - Petr Neužil
- Department of Cardiology, Homolka Hospital, Prague, Czechia (V.Y.R., P.N.)
| | - Ian G Crozier
- Department of Cardiology, Christchurch Hospital, New Zealand (M.D., I.M., I.G.C.)
| |
Collapse
|
4
|
O’Donnell D, Haqqani HM, Kotschet E, Shaw D, Prabhu A, Roubos N, Alison JF, Melton IC, Denman RA, Lin T, Almeida A, Thompson A, Portway B, Sawchuk RT, Lande J, Liang S, Lentz L, DeGroot PJ, Crozier IG. B-PO04-065 TWO-YEAR CHRONIC FOLLOW-UP FROM THE PILOT STUDY OF A SUBSTERNAL EXTRAVASCULAR IMPLANTABLE CARDIOVERTER DEFIBRILLATOR. Heart Rhythm 2021. [DOI: 10.1016/j.hrthm.2021.06.761] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
5
|
Elliott JM, Crozier IG. Decreases in cardiac catheter laboratory workload during the COVID-19 level 4 lockdown in New Zealand. Intern Med J 2020; 50:1000-1003. [PMID: 32881225 PMCID: PMC7436864 DOI: 10.1111/imj.14922] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2020] [Accepted: 05/20/2020] [Indexed: 01/15/2023]
Abstract
An increase in coronavirus disease (COVID-19) infections prompted Level 4 lockdown throughout New Zealand from 25 March 2020. We have investigated trends in coronary and electrophysiology (EP) procedures before and during this lockdown. The number of acute procedures for ST elevation myocardial infarction remained stable. In contrast, the number of in-patient angiograms and percutaneous intervention procedures fell by 53% compared with the previous 4 weeks in 2020 and by 56% compared with the corresponding period in 2019. Further study is required to determine the reasons for these trends.
Collapse
Affiliation(s)
- John M Elliott
- Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand.,Department of Cardiology, Christchurch Public Hospital, Christchurch, New Zealand
| | - Ian G Crozier
- Department of Cardiology, Christchurch Public Hospital, Christchurch, New Zealand
| |
Collapse
|
6
|
Boersma LV, Merkely B, Neuzil P, Crozier IG, Akula DN, Timmers L, Kalarus Z, Sherfesee L, DeGroot PJ, Thompson AE, Lexcen DR, Knight BP. Therapy From a Novel Substernal Lead. JACC Clin Electrophysiol 2019; 5:186-196. [DOI: 10.1016/j.jacep.2018.11.003] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2018] [Revised: 10/11/2018] [Accepted: 11/01/2018] [Indexed: 10/27/2022]
|
7
|
Gardner RJM, Crozier IG, Binfield AL, Love DR, Lehnert K, Gibson K, Lintott CJ, Snell RG, Jacobsen JC, Jones PP, Waddell-Smith KE, Kennedy MA, Skinner JR. Penetrance and expressivity of the R858H CACNA1C variant in a five-generation pedigree segregating an arrhythmogenic channelopathy. Mol Genet Genomic Med 2018; 7:e00476. [PMID: 30345660 PMCID: PMC6382452 DOI: 10.1002/mgg3.476] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2018] [Revised: 08/22/2018] [Accepted: 08/23/2018] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND Isolated cardiac arrhythmia due to a variant in CACNA1C is of recent knowledge. Most reports have been of singleton cases or of quite small families, and estimates of penetrance and expressivity have been difficult to obtain. We here describe a large pedigree, from which such estimates have been calculated. METHODS We studied a five-generation family, in which a CACNA1C variant c.2573G>A p.Arg858His co-segregates with syncope and cardiac arrest, documenting electrocardiographic data and cardiac symptomatology. The reported patients/families from the literature with CACNA1C gene variants were reviewed, and genotype-phenotype correlations are drawn. RESULTS The range of phenotype in the studied family is wide, from no apparent effect, through an asymptomatic QT interval prolongation on electrocardiography, to episodes of presyncope and syncope, ventricular fibrillation, and sudden death. QT prolongation showed inconsistent correlation with functional cardiology. Based upon analysis of 28 heterozygous family members, estimates of penetrance and expressivity are derived. CONCLUSIONS These estimates of penetrance and expressivity, for this specific variant, may be useful in clinical practice. Review of the literature indicates that individual CACNA1C variants have their own particular genotype-phenotype correlations. We suggest that, at least in respect of the particular variant reported here, "arrhythmogenic channelopathy" may be a more fitting nomenclature than long QT syndrome.
Collapse
Affiliation(s)
- R J McKinlay Gardner
- Cardiac Inherited Disease Group, Auckland, New Zealand.,Genetic Health Service New Zealand (South Island Hub), Christchurch Hospital, Christchurch, New Zealand.,Clinical Genetics Group, Department of Women's and Children's Health, University of Otago, Dunedin, New Zealand
| | - Ian G Crozier
- Cardiac Inherited Disease Group, Auckland, New Zealand.,Department of Cardiology, Christchurch Hospital, Christchurch, New Zealand
| | - Alex L Binfield
- Cardiac Inherited Disease Group, Auckland, New Zealand.,Department of Paediatrics, Christchurch Hospital, Christchurch, New Zealand.,Department of Paediatrics, University of Otago, Christchurch, New Zealand
| | - Donald R Love
- Cardiac Inherited Disease Group, Auckland, New Zealand.,LabPlus, Auckland City Hospital, Auckland, New Zealand
| | - Klaus Lehnert
- Cardiac Inherited Disease Group, Auckland, New Zealand.,School of Biological Sciences, University of Auckland, Auckland, New Zealand
| | - Kate Gibson
- Cardiac Inherited Disease Group, Auckland, New Zealand.,Genetic Health Service New Zealand (South Island Hub), Christchurch Hospital, Christchurch, New Zealand
| | - Caroline J Lintott
- Cardiac Inherited Disease Group, Auckland, New Zealand.,Genetic Health Service New Zealand (South Island Hub), Christchurch Hospital, Christchurch, New Zealand
| | - Russell G Snell
- Cardiac Inherited Disease Group, Auckland, New Zealand.,School of Biological Sciences, University of Auckland, Auckland, New Zealand
| | - Jessie C Jacobsen
- Cardiac Inherited Disease Group, Auckland, New Zealand.,School of Biological Sciences, University of Auckland, Auckland, New Zealand
| | - Peter P Jones
- Cardiac Inherited Disease Group, Auckland, New Zealand.,Department of Physiology and HeartOtago, University of Otago, Dunedin, New Zealand
| | - Kathryn E Waddell-Smith
- Cardiac Inherited Disease Group, Auckland, New Zealand.,Department of Cardiology, Auckland City Hospital, Auckland, New Zealand
| | - Martin A Kennedy
- Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand
| | - Jonathan R Skinner
- Cardiac Inherited Disease Group, Auckland, New Zealand.,Department of Cardiology, Auckland City Hospital, Auckland, New Zealand
| |
Collapse
|
8
|
Daly MG, Melton I, Roper G, Lim G, Crozier IG. High-Resolution Infrared Thermography of Esophageal Temperature During Radiofrequency Ablation of Atrial Fibrillation. Circ Arrhythm Electrophysiol 2018; 11:e005667. [DOI: 10.1161/circep.117.005667] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2017] [Accepted: 12/06/2017] [Indexed: 11/16/2022]
Affiliation(s)
| | | | | | - Gary Lim
- From the Christchurch Hospital, New Zealand
| | | |
Collapse
|
9
|
Chan WYW, Charles CJ, Frampton CM, Richards AM, Crozier IG, Troughton RW, Jardine DL. Human muscle sympathetic nerve responses to urocortin-2 in health and stable heart failure. Clin Exp Pharmacol Physiol 2015; 42:888-895. [DOI: 10.1111/1440-1681.12449] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2014] [Revised: 06/11/2015] [Accepted: 06/19/2015] [Indexed: 11/28/2022]
Affiliation(s)
- W Y Wandy Chan
- Department of Medicine; Christchurch Heart Institute; University of Otago; Christchurch New Zealand
- Advanced Heart Failure and Cardiac Transplant Unit; The Prince Charles Hospital; Brisbane QLD Australia
| | - Christopher J Charles
- Department of Medicine; Christchurch Heart Institute; University of Otago; Christchurch New Zealand
| | - Christopher M Frampton
- Department of Medicine; Christchurch Heart Institute; University of Otago; Christchurch New Zealand
| | - A Mark Richards
- Department of Medicine; Christchurch Heart Institute; University of Otago; Christchurch New Zealand
| | - Ian G Crozier
- Department of Medicine; Christchurch Heart Institute; University of Otago; Christchurch New Zealand
| | - Richard W Troughton
- Department of Medicine; Christchurch Heart Institute; University of Otago; Christchurch New Zealand
| | - David L Jardine
- Department of Medicine; Christchurch Heart Institute; University of Otago; Christchurch New Zealand
| |
Collapse
|
10
|
Crozier IG, Theuns DA. Patients with congenital heart disease: how to determine the eligibility for implantation of a subcutaneous implantable defibrillator? Europace 2015; 17:1003-4. [DOI: 10.1093/europace/euv087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
11
|
Chan WYW, Blomqvist A, Melton IC, Norén K, Crozier IG, Benser ME, Eigler NL, Gutfinger D, Troughton RW. Effects of AV delay and VV delay on left atrial pressure and waveform in ambulant heart failure patients: insights into CRT optimization. Pacing Clin Electrophysiol 2014; 37:810-9. [PMID: 24502608 DOI: 10.1111/pace.12362] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/13/2012] [Revised: 12/14/2013] [Accepted: 12/17/2013] [Indexed: 12/21/2022]
Abstract
BACKGROUND We hypothesized that left atrial pressure (LAP) obtained by a permanent implantable sensor is sensitive to changes in cardiac resynchronization therapy (CRT) settings and could guide CRT optimization to improve the response rate. We investigated the effect of CRT optimization on LAP and its waveform parameters in ambulant heart failure (HF) patients. METHODS CRT optimization was performed in eight ambulant HF patients, using echocardiography as reference. LAP waveform was acquired at each of eight atrioventricular (AV) intervals and five inter-ventricular (VV) intervals. Selected waveform parameters were also evaluated for their sensitivity to CRT changes and agreement with echocardiography-guided optimal settings. RESULTS Optimal AV and VV intervals varied considerably between patients. All patients exhibited significant changes in waveform morphology with AV optimization. Optimal AV delay determined from echocardiography ranged between 140 ms and 225 ms. Mean LAP tended to be lower at optimal setting 14 ± 3 mmHg compared to shorter (<100 ms) or longer (>160 ms) AV settings (P = 0.16). There were clear trends to smaller peak a-wave (P = 0.11) and gentler positive a-slope (P = 0.15) and positive v-slope (P = 0.09) with longer AV delays. Mean LAP and negative v-wave slope correlated well with echo-guided optimal setting, r = 0.91 (P = 0.001) and 0.79 (P = 0.03), respectively. No significant effects on LAP or waveform were seen during VV optimization. CONCLUSIONS LAP and its waveform changes considerably with AV optimization. There is good agreement between echo-guided optimal setting and LAP. LAP could provide an objective guide to CRT optimization. (Clinical Trial Registry information: URL: http://www.clinicaltrials.gov. Unique Identifier: NCT00632372).
Collapse
Affiliation(s)
- W Y Wandy Chan
- Cardiology Department, Christchurch Hospital, Christchurch, New Zealand
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Roberts A, Trainor KE, Weeks B, Jackson N, Troughton RW, Charles CJ, Rademaker MT, Melton IC, Crozier IG, Hafelfinger W, Gutfinger DE, Eigler NL, Abraham WT, Clubb FJ. Integrated microscopy techniques for comprehensive pathology evaluation of an implantable left atrial pressure sensor. J Histotechnol 2013; 36:17-24. [PMID: 25258469 PMCID: PMC4161197 DOI: 10.1179/2046023613y.0000000021] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
The safety and efficacy of an implantable left atrial pressure (LAP) monitoring system is being evaluated in a clinical trial setting. Because the number of available specimens from the clinical trial for histopathology analysis is limited, it is beneficial to maximize the usage of each available specimen by relying on integrated microscopy techniques. The aim of this study is to demonstrate how a comprehensive pathology analysis of a single specimen may be reliably achieved using integrated microscopy techniques. Integrated microscopy techniques consisting of high-resolution gross digital photography followed by micro-computed tomography (micro-CT) scanning, low-vacuum scanning electron microscopy (LVSEM), and microground histology with special stains were applied to the same specimen. Integrated microscopy techniques were applied to eight human specimens. Micro-CT evaluation was beneficial for pinpointing the location and position of the device within the tissue, and for identifying any areas of interest or structural flaws that required additional examination. Usage of LVSEM was reliable in analyzing surface topography and cell type without destroying the integrity of the specimen. Following LVSEM, the specimen remained suitable for embedding in plastic and sectioning for light microscopy, using the positional data gathered from the micro-CT to intersect areas of interest in the slide. Finally, hematoxylin and eosin (H&E) and methylene blue staining was deployed on the slides with high-resolution results. The integration of multiple techniques on a single specimen maximized the usage of the limited number of available specimens from the clinical trial setting. Additionally, this integrated microscopic evaluation approach was found to have the added benefit of providing greater assurance of the derived conclusions because it was possible to cross-validate the results from multiple tests on the same specimen.
Collapse
Affiliation(s)
- A Roberts
- Department of Veterinary Pathobiology, Texas A&M University, College Station, TX, USA
| | - K E Trainor
- Department of Veterinary Pathobiology, Texas A&M University, College Station, TX, USA
| | - B Weeks
- Department of Veterinary Pathobiology, Texas A&M University, College Station, TX, USA
| | - N Jackson
- Department of Veterinary Pathobiology, Texas A&M University, College Station, TX, USA
| | - R W Troughton
- Department of Cardiology, Christchurch Hospital and University of Otago, Christchurch, New Zealand
| | - C J Charles
- Department of Cardiology, Christchurch Hospital and University of Otago, Christchurch, New Zealand
| | - M T Rademaker
- Department of Cardiology, Christchurch Hospital and University of Otago, Christchurch, New Zealand
| | - I C Melton
- Department of Cardiology, Christchurch Hospital and University of Otago, Christchurch, New Zealand
| | - I G Crozier
- Department of Cardiology, Christchurch Hospital and University of Otago, Christchurch, New Zealand
| | - W Hafelfinger
- St. Jude Medical, Cardiac Rhythm Management Division, Sylmar, CA, USA
| | - D E Gutfinger
- St. Jude Medical, Cardiac Rhythm Management Division, Sylmar, CA, USA
| | - N L Eigler
- St. Jude Medical, Cardiac Rhythm Management Division, Sylmar, CA, USA
| | - W T Abraham
- Division of Cardiovascular Medicine, Ohio State University, Columbus, OH, USA
| | - F J Clubb
- Department of Veterinary Pathobiology, Texas A&M University, College Station, TX, USA
| |
Collapse
|
13
|
Chan WYW, Frampton CM, Crozier IG, Troughton RW, Richards AM. Urocortin-2 infusion in acute decompensated heart failure: findings from the UNICORN study (urocortin-2 in the treatment of acute heart failure as an adjunct over conventional therapy). JACC Heart Fail 2013; 1:433-41. [PMID: 24621976 DOI: 10.1016/j.jchf.2013.07.003] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/15/2013] [Revised: 07/08/2013] [Accepted: 07/15/2013] [Indexed: 01/08/2023]
Abstract
OBJECTIVES The purpose of this study is to investigate the effects of urocortin-2 as adjunct therapy in acute decompensated heart failure (ADHF). BACKGROUND Urocortin-2 produced favorable integrated effects in experimental heart failure but there are no equivalent human data. We describe the first therapeutic study of urocortin-2 infusion in ADHF. METHODS Fifty-three patients with ADHF were randomly assigned to 5 ng/kg/min of urocortin-2 or placebo infusion for 4 h as an adjunct therapy. Changes in vital signs, plasma neurohormonal and renal indices during treatment were compared using repeated-measures analysis of covariance. Ten patients in each arm underwent more detailed invasive hemodynamic evaluation. RESULTS Urocortin-2 produced greater falls in systolic blood pressure compared to placebo (16 ± 5.8 mm Hg, p < 0.001) with nonsignificant increases in heart rate (5.7 ± 3.8 beats/min, p = 0.07) and increased cardiac output (2.1 ± 0.4 l/min vs. -0.1 ± 0.4 l/min, p < 0.001) associated with a 47% reduction in calculated total peripheral resistance (p = 0.015). Falls in pulmonary artery and pulmonary capillary wedge pressures did not differ significantly between groups. Urocortin-2 reduced urine volume and creatinine clearance during infusion but these returned to above baseline level in the 8 h after infusion. Plasma renin activity rose briefly with urocortin-2 coinciding with reductions in blood pressure (p < 0.001). B-type natriuretic peptide levels fell significantly over 24 h with urocortin-2 (p < 0.01) but not with placebo. CONCLUSIONS Urocortin-2 infusion in ADHF markedly augmented cardiac output without significant reflex tachycardia. Renal indices fell transiently concurrent with urocortin-2-induced reductions in blood pressure. Further investigations are required to uncover the full potential of urocortin-2 in treating ADHF.
Collapse
Affiliation(s)
- W Y Wandy Chan
- Christchurch Heart Institute, University of Otago, Christchurch, New Zealand; Cardiology Department, Christchurch Hospital, Christchurch, New Zealand.
| | | | - Ian G Crozier
- Cardiology Department, Christchurch Hospital, Christchurch, New Zealand
| | - Richard W Troughton
- Christchurch Heart Institute, University of Otago, Christchurch, New Zealand; Cardiology Department, Christchurch Hospital, Christchurch, New Zealand
| | - A Mark Richards
- Christchurch Heart Institute, University of Otago, Christchurch, New Zealand; Cardiovascular Research Institute, National University Health System, Singapore
| |
Collapse
|
14
|
Bellaney LM, Bridgman PG, Crozier IG, Melton IC. Decline in echocardiographic optimisation of cardiac resynchronisation therapy (CRT) devices at Christchurch Hospital. N Z Med J 2013; 126:95-96. [PMID: 23797085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
|
15
|
Aldous SJ, Florkowski CM, Crozier IG, Than MP. The performance of high sensitivity troponin for the diagnosis of acute myocardial infarction is underestimated. Clin Chem Lab Med 2012; 50:727-9. [DOI: 10.1515/cclm.2011.830] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2011] [Accepted: 11/21/2011] [Indexed: 11/15/2022]
Abstract
AbstractMany papers evaluating high sensitivity troponin assays make the diagnosis of myocardial infarction based on conventional troponin assays in clinical use at the time of recruitment. Such analyses often do not show superiority of high sensitivity assays compared with contemporary assays meeting precision guidelines.Three hundred and twenty-two patients presenting to the emergency department between November 2006 and April 2007 for evaluation for acute coronary syndrome had serial (0 h and >6 h) bloods taken to compare troponin assays (Roche hsTnT, Abbott TnI, Roche TnT and Vitros TnI). The diagnosis of myocardial infarction was made using each troponin assay separately with which that same assay was analysed for diagnostic performance.The rate of myocardial infarction would be 38.9% using serial hsTnT, 31.3% using serial Abbott TnI, 27.1% using serial TnT and 26.4% using serial Vitros TnI. The baseline sensitivities (0 h) are 89.9% (85.2–93.3) for hsTnT, 77.9% (71.0–87.5) for Abbott TnI, 73.0% (65.6–78.7) for TnT and 86.8% (74.6–94.4%) for Vitros TnI. The specificities (peak 0 h and >6 h samples) are 93.1% (91.2–93.1) for hsTnT, 88.3% (86.5–88.3) for Abbott TnI, 92.2% (90.5–92.2) for TnT and 90.6% (70.1–90.6) for Vitros TnI.hsTnT has superior sensitivity for myocardial infarction than even assays at or near guideline precision requirements (Abbott and Vitros TnI). The specificity of hsTnT assay is not as poor as previous analyses suggest.
Collapse
|
16
|
Coolbear F, Crozier IG. Surgical radiofrequency ablation for atrial fibrillation: the Christchurch, New Zealand experience. N Z Med J 2011; 124:33-38. [PMID: 21964011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
AIMS To report the long-term results following surgical radiofrequency ablation (RFA) for atrial fibrillation as an adjunct to other cardiac surgery at Christchurch Hospital. METHODS A retrospective observational audit review of outcomes. The sample population included all patients identified as having undergone surgical RFA for atrial fibrillation at Christchurch Hospital, between the first procedure performed on 2 July 2001 and 28 January 2009. RESULTS A total of 44 patients underwent surgical RFA between 2 July 2001 and 28 January 2009. Postoperatively there were three deaths prior to discharge (7%). Pacemakers were required in four patients (9%), and two patients subsequently underwent catheter ablation for atrial arrhythmias. In the immediate postoperative period only three patients remained in atrial fibrillation. At last follow-up up to 102 months from surgery (45 plus or minus 29 months), 27 patients had developed persistent atrial fibrillation and four persistent atrial flutter. Persisting long-term benefit was seen in seven patients (18%, 7/38); five patients were in stable sinus rhythm, one had paroxysmal atrial fibrillation and one paroxysmal atrial flutter. CONCLUSIONS Whilst the procedure was effectively acutely, the recurrence of atrial fibrillation was high and development of new atrial flutter common over long-term follow-up.
Collapse
Affiliation(s)
- Frith Coolbear
- Department of Cardiology, Christchurch Hospital, PO Box 4345, Christchurch, New Zealand
| | | |
Collapse
|
17
|
Daly M, Melton I, Crozier IG. Pulmonary vein ablation for atrial fibrillation: the Christchurch, New Zealand experience. N Z Med J 2011; 124:39-47. [PMID: 21964012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
AIMS To report the long-term results following percutaneous pulmonary vein ablation (PVA) for atrial fibrillation (AF) at Christchurch Hospital. METHODS A retrospective observational audit review of outcomes. The sample population included all patients identified as having undergone percutaneous radiofrequency ablation of multiple pulmonary veins at Christchurch Hospital, from the first procedure performed on 29 September 2001 until 15 December 2009. RESULTS A total of 187 patients underwent pulmonary vein ablation. The patient population was predominantly younger (mean age 51) and male (83%) with no important comorbidity. Following a single procedure only, the chance of remaining free of AF at 12 months was 0.74 for patients with paroxysmal AF (PAF) and 0.60 for patients with persistent AF (PsAF). 52 patients (28%) underwent a repeat procedure within 12 months of their index ablation owing to early recurrence of AF. 5-year survival free of clinical AF when analysed following these early repeat procedures, if required, was 0.74 and 0.56 for PAF and PsAF patients respectively. Complications occurred following 6% of procedures and were serious in 2.5%. New atrial flutter developed in 6% of patients. CONCLUSIONS PVA is an effective treatment for AF, with better outcomes in patients with paroxysmal atrial fibrillation. However, as it carries a significant risk, we recommend that its application be reserved for patients with highly symptomatic, medication-refractory disease.
Collapse
Affiliation(s)
- Matthew Daly
- Department of Cardiology, Christchurch Hospital, PO Box 4345, Christchurch, New Zealand
| | | | | |
Collapse
|
18
|
Hamid AK, Richards AM, Crozier IG, Lainchbury JG, Melton I, Bridgman PG, Palmer SC, Frampton CM, Nicholls MG. Prediction of cardiac rhythm 1 year following cardioversion for atrial fibrillation. N Z Med J 2011; 124:48-56. [PMID: 21964013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
BACKGROUND There is little recent information regarding outcome and its determinants following cardioversion (CV) for atrial fibrillation (AF) or flutter. This study aims to help improve prediction of cardiac rhythm outcome following CV for AF. METHODS Cardiac rhythm at 6 weeks and 12 months was documented following elective (EC; n=496) or immediate (IC; n=52) cardioversion for AF or atrial flutter in a single referral centre. RESULTS 65 and 58% of IC patients remained in sinus rhythm (SR) 6 weeks and 1 year after CV (respectively) compared with 43% and 30% in EC patients (P<0.001). Independent positive predictors of SR 6 weeks after cardioversion included amiodarone therapy (OR 2.04 [1.28-3.33], P<0.01) and atrial flutter (OR 1.85 [1.09-3.13], P<0.05). Negative predictors included the need for >1 shock to achieve SR (OR 1.61 [1.12-2.37], P=0.011) and arrhythmia duration, (OR 0.96 [0.95-0.97], P<0.001). At 1 year, amiodarone, duration of arrhythmia and the need for >1 shock remained independent predictors of rhythm. CONCLUSIONS The number of shocks required to achieve SR is a newly demonstrated independent predictor of rhythm outcome after elective CV.
Collapse
Affiliation(s)
- Amjad K Hamid
- Department of Medicine, Otago University-Christchurch, Christchurch, New Zealand.
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
MacCormick JM, Crawford JR, Chung SK, Shelling AN, Evans CA, Rees MI, Smith WM, Crozier IG, McAlister H, Skinner JR. Symptoms and Signs Associated with Syncope in Young People with Primary Cardiac Arrhythmias. Heart Lung Circ 2011; 20:593-8. [DOI: 10.1016/j.hlc.2011.04.036] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2011] [Revised: 04/21/2011] [Accepted: 04/27/2011] [Indexed: 10/18/2022]
|
20
|
Aldous SJ, Florkowski CM, Crozier IG, Elliott J, George P, Lainchbury JG, Mackay RJ, Than M. Comparison of high sensitivity and contemporary troponin assays for the early detection of acute myocardial infarction in the emergency department. Ann Clin Biochem 2011; 48:241-8. [DOI: 10.1258/acb.2010.010219] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Background Current guidelines define acute myocardial infarction (AMI) by the rise and/or fall of cardiac troponin with ≥1 value above the 99th percentile. Past troponin assays have been unreliable at the lower end of the range. Highly sensitive assays have therefore been developed to increase the clinical sensitivity for detection of myocardial injury. Methods Three hundred and thirty-two patients with chest pain suggestive of AMI were prospectively recruited between November 2006 and April 2007. Serial blood samples were analysed to compare Roche Elecsys high sensitivity troponin T (hsTnT), Abbott Architect troponin I 3rd generation (TnI 3) and Roche Elecsys troponin T (TnT) for the diagnosis of AMI. Results One hundred and ten (33.1%) patients were diagnosed with AMI. Test performance for the diagnosis of AMI, as quantified by receiver operating characteristic area under the curve (95% confidence intervals) for baseline/follow-up troponins were as follows: hsTnT 0.90 (0.87–0.94)/0.94 (0.91–0.97), TnI 3 0.88 (0.84–0.92)/0.93 (0.90–0.96) and TnT 0.80 (0.74–0.85)/0.89 (0.85–0.94). hsTnT was superior to TnT ( P < 0.001/0.013 at baseline/follow-up) but equivalent to TnI 3. For patients with a final diagnosis of AMI, baseline troponins were raised in more patients for hsTnT (83.6%) than TnI 3 (74.5%) and TnT (62.7%). A delta troponin of ≥20% increased the specificity of hsTnT from 80.6% to 93.7% but reduced sensitivity from 90.9% to 71.8%. Conclusion hsTnT was superior to TnT but equivalent to TnI 3 for the diagnosis of AMI. Serial troponin measurement increased test performance. hsTnT was the most likely to be raised at baseline in those with AMI. A delta troponin increases specificity but reduces sensitivity.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Martin Than
- Emergency Department, Christchurch Hospital, Riccarton Road, Christchurch, New Zealand
| |
Collapse
|
21
|
Aldous SJ, Florkowski CM, Crozier IG, George P, Mackay R, Than M. High sensitivity troponin outperforms contemporary assays in predicting major adverse cardiac events up to two years in patients with chest pain. Ann Clin Biochem 2011; 48:249-55. [DOI: 10.1258/acb.2010.010220] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Background Previous studies have shown a risk of subsequent major adverse cardiovascular events (MACEs) in patients with suspected acute coronary syndromes (ACSs) and elevated cardiac troponin. The aim of this study was to compare prognostic utility of high-sensitivity troponin with contemporary troponin assays in such patients. Methods In total, 332 patients with suspected ACS were investigated between November 2006 and April 2007; all were followed for two years. Blood samples were analysed to compare Roche Elecsys high-sensitivity troponin T (hsTnT), Abbott Architect troponin I 3rd generation (TnI 3) and Roche Elecsys troponin T (TnT), for the prediction of MACE (composite of cardiovascular death, non-fatal myocardial infarction and revascularization). Results Sixty-eight patients (20.5%) experienced MACE between discharge and two years. Receiver operating characteristic (ROC) curve derived area under the ROC curve (95% confidence intervals) for baseline hsTnT were 0.70 (0.63–0.76), TnI 3 0.66 (0.59–0.73) and TnT 0.61 (0.53–0.69). hsTnT ( P = 0.001) was superior to TnT and TnI 3 trended ( P = 0.094) to superiority but were equivalent to each other. hsTnT best stratified patients with cumulative event rates for two-year MACE of 35.6% for levels ≥99th percentile, 17.9% for levels between the limit of detection (LOD) and 99th percentile and 5.4% for levels <LOD compared with TnI 3: 33.0%, 31.1% and 10.9%, respectively. TnT had MACE rates of 36.7% when ≥99th percentile and 15.4% when <99th percentile (=LOD). Conclusions hsTnT outperformed contemporary TnI and TnT assays for the prediction of MACE at two years. Those with levels below the LOD for hsTnT identified a group of patients at very low risk for adverse events.
Collapse
Affiliation(s)
| | | | | | | | | | - Martin Than
- Emergency Department, Christchurch Hospital, Riccarton Road, Christchurch, New Zealand
| |
Collapse
|
22
|
Troughton RW, Ritzema J, Eigler NL, Melton IC, Krum H, Adamson PB, Kar S, Shah PK, Whiting JS, Heywood JT, Rosero S, Singh JP, Saxon L, Matthews R, Crozier IG, Abraham WT. Direct left atrial pressure monitoring in severe heart failure: long-term sensor performance. J Cardiovasc Transl Res 2010; 4:3-13. [PMID: 20945124 PMCID: PMC3018612 DOI: 10.1007/s12265-010-9229-z] [Citation(s) in RCA: 68] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/07/2010] [Accepted: 09/27/2010] [Indexed: 12/30/2022]
Abstract
We report the stability, accuracy, and development history of a new left atrial pressure (LAP) sensing system in ambulatory heart failure (HF) patients. A total of 84 patients with advanced HF underwent percutaneous transseptal implantation of the pressure sensor. Quarterly noninvasive calibration by modified Valsalva maneuver was achieved in all patients, and 96.5% of calibration sessions were successful with a reproducibility of 1.2 mmHg. Absolute sensor drift was maximal after 3 months at 4.7 mmHg (95% CI, 3.2–6.2 mmHg) and remained stable through 48 months. LAP was highly correlated with simultaneous pulmonary wedge pressure at 3 and 12 months (r = 0.98, average difference of 0.8 ± 4.0 mmHg). Freedom from device failure was 95% (n = 37) at 2 years and 88% (n = 12) at 4 years. Causes of failure were identified and mitigated with 100% freedom from device failure and less severe anomalies in the last 41 consecutive patients (p = 0.005). Accurate and reliable LAP measurement using a chronic implanted monitoring system is safe and feasible in patients with advanced heart failure.
Collapse
|
23
|
Bardy GH, Smith WM, Hood MA, Crozier IG, Melton IC, Jordaens L, Theuns D, Park RE, Wright DJ, Connelly DT, Fynn SP, Murgatroyd FD, Sperzel J, Neuzner J, Spitzer SG, Ardashev AV, Oduro A, Boersma L, Maass AH, Van Gelder IC, Wilde AA, van Dessel PF, Knops RE, Barr CS, Lupo P, Cappato R, Grace AA. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med 2010; 363:36-44. [PMID: 20463331 DOI: 10.1056/nejmoa0909545] [Citation(s) in RCA: 533] [Impact Index Per Article: 38.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
BACKGROUND Implantable cardioverter-defibrillators (ICDs) prevent sudden death from cardiac causes in selected patients but require the use of transvenous lead systems. To eliminate the need for venous access, we designed and tested an entirely subcutaneous ICD system. METHODS First, we conducted two short-term clinical trials to identify a suitable device configuration and assess energy requirements. We evaluated four subcutaneous ICD configurations in 78 patients who were candidates for ICD implantation and subsequently tested the best configuration in 49 additional patients to determine the subcutaneous defibrillation threshold in comparison with that of the standard transvenous ICD. Then we evaluated the long-term use of subcutaneous ICDs in a pilot study, involving 6 patients, which was followed by a trial involving 55 patients. RESULTS The best device configuration consisted of a parasternal electrode and a left lateral thoracic pulse generator. This configuration was as effective as a transvenous ICD for terminating induced ventricular fibrillation, albeit with a significantly higher mean (+/-SD) energy requirement (36.6+/-19.8 J vs. 11.1+/-8.5 J). Among patients who received a permanent subcutaneous ICD, ventricular fibrillation was successfully detected in 100% of 137 induced episodes. Induced ventricular fibrillation was converted twice in 58 of 59 patients (98%) with the delivery of 65-J shocks in two consecutive tests. Clinically significant adverse events included two pocket infections and four lead revisions. After a mean of 10+/-1 months, the device had successfully detected and treated all 12 episodes of spontaneous, sustained ventricular tachyarrhythmia. CONCLUSIONS In small, nonrandomized studies, an entirely subcutaneous ICD consistently detected and converted ventricular fibrillation induced during electrophysiological testing. The device also successfully detected and treated all 12 episodes of spontaneous, sustained ventricular tachyarrhythmia. (ClinicalTrials.gov numbers, NCT00399217 and NCT00853645.)
Collapse
Affiliation(s)
- Gust H Bardy
- Seattle Institute for Cardiac Research, Seattle, WA, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Park RE, Greenslade JM, Matthewson SP, MacDonald SL, Melton IC, Crozier IG. OUTCOMES OF PULMONARY VEIN ISOLATION ABLATION FOR ATRIAL FIBRILLATION. Heart Lung Circ 2008. [DOI: 10.1016/j.hlc.2008.03.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
25
|
Park RE, Ritzema JLT, Melton IC, Crozier IG, Richards AM, Troughton RW. COMPARISON OF INTRATHORACIC IMPEDANCE WITH DIRECT LEFT ATRIAL PRESSURE IN CHRONIC HEART FAILURE. Heart Lung Circ 2008. [DOI: 10.1016/j.hlc.2008.03.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
26
|
Ritzema-Carter JLT, Smyth D, Troughton RW, Crozier IG, Melton IC, Richards AM, Eigler N, Whiting J, Kar S, Krum H, Abraham WT. Dynamic Myocardial Ischemia Caused by Circumflex Artery Stenosis Detected by a New Implantable Left Atrial Pressure Monitoring Device. Circulation 2006; 113:e705-6. [PMID: 16618824 DOI: 10.1161/circulationaha.105.572040] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
27
|
Richards M, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, Frampton CM, Crozier IG, Yandle TG, Doughty R, MacMahon S, Sharpe N. Comparison of B-Type Natriuretic Peptides for Assessment of Cardiac Function and Prognosis in Stable Ischemic Heart Disease. J Am Coll Cardiol 2006; 47:52-60. [PMID: 16386664 DOI: 10.1016/j.jacc.2005.06.085] [Citation(s) in RCA: 127] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/19/2005] [Revised: 04/28/2005] [Accepted: 06/13/2005] [Indexed: 11/29/2022]
Abstract
UNLABELLED In 1,049 patients with stable ischemic heart disease (IHD), brain natriuretic peptide (BNP) and amino terminal pro-brain natriuretic peptide (NTproBNP) correlated closely (r = 0.09, p < 0.001) and were similarly related to left ventricular ejection fraction (LVEF) (r = -0.50 and -0.46, respectively), age (0.44 and 0.47), and creatinine clearance (-0.51 and -0.51). Receiver-operating characteristic curves for detection of LVEF <30% were similar (area under the curves = 0.83 and 0.80, both p < 0.001), and both peptides had strong negative predictive value (95% and 94%). Both independently predicted all-cause mortality and/or heart failure with closely overlapping event-free survival curves; BNP and NTproBNP display strong, near-identical test performance in ruling about severely reduced LVEF and in prediction of all-cause mortality or heart failure in stable IHD. OBJECTIVES The aim of this work was to test B-type natriuretic peptides for assessment of function and prognosis in stable ischemic heart disease (IHD) and to compare brain natriuretic peptide (BNP) with amino terminal pro-brain natriuretic peptide (NTproBNP), including the relative effects of age and renal function on test performance. BACKGROUND Brain natriuretic peptide and NTproBNP are emerging diagnostic and prognostic markers in heart failure and acute coronary syndromes. Their performance in assessing function and prognosis in stable IHD is unknown. Whether one marker is superior and the relative effects of age and renal function on test performance are uncertain. METHODS In 1,049 patients with stable IHD, left ventricular ejection fraction (LVEF) was measured by radionuclide scanning and creatinine clearance estimated by the Cockroft-Gault equation. Age, gender, and body mass index were recorded. Twelve-month all-cause mortality or admission with heart failure was prospectively recorded; BNP and NTproBNP were measured by radioimmunoassay. RESULTS Brain natriuretic peptide and NTproBNP correlated closely (r = 0.90, p < 0.001) and had similar relationships to LVEF (r = -0.50 and -0.46, respectively, both p < 0.001), age (0.44 and 0.47, both p < 0.001), and creatinine clearance (-0.51 and -0.51, both p < 0.001). Areas under receiver-operating characteristic curves for detection of LVEF <30% were similar (0.83 and 0.80, both p < 0.001) with strong negative predictive values for both (95% and 94%). Both markers independently predicted the clinical end point with closely overlapping event-free survival curves. CONCLUSIONS In stable IHD, BNP and NTproBNP display strong and near-identical test performance in ruling out severely reduced LVEF and in prediction of all-cause mortality or heart failure despite significant effects of age, gender, and renal function on levels of both markers.
Collapse
Affiliation(s)
- Mark Richards
- Christchurch Cardioendocrine Research Group, Christchurch Hospital, Christchurch, New Zealand.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Hillock RJ, Melton IC, Crozier IG. Radiofrequency ablation for common atrial flutter using an 8-mm tip catheter and up to 150 W. Europace 2005; 7:409-12. [PMID: 16087101 DOI: 10.1016/j.eupc.2005.03.002] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2004] [Revised: 02/21/2005] [Accepted: 03/06/2005] [Indexed: 11/23/2022] Open
Abstract
The formation of bi-directional block in atrial flutter can be adversely affected by problems with the delivery of effective energy related to isthmus anatomy and contact. Higher energies can produce larger and more effective lesions. The optimum setting for power delivery using temperature controlled ablation has not been established, with the maximum reported being 100 W. This is a retrospective review of the first 50 new cases assessing the efficacy and safety of using temperature controlled (60-65 degrees C) flutter ablation with an 8mm tip electrode catheter and up to 150 W. All cases had either typical flutter alone (34%) or predominant flutter as the indication, no combined procedures were included. Acute procedural success was 94% and long-term success of 88%. Median number of ablations required was 11 (interquartile range 10-19), median procedure time 120 min (IQR 102-164), fluoroscopy time 22 min (IQR 17-36), radiation dose 17 Gy cm(2) (IQR 10-27), median number of lines 1 (IQR 1-2). Six patients achieved 150 W, but 42 achieved >100 W (median watts 142 W, IQR 104-147). Patients (12%) experienced an uncomplicated pop during the procedure. None experienced a significant complication. There were three late relapses. The setting of 150 W maximum delivered energy in temperature regulated ablation allowed higher energies (>100 W) to be delivered in most patients. This resulted in acute and long-term success rates that compare well with the literature but is associated with a 12% rate of pop. Subsequent to this series our 54th patient sustained a pop due to high energy ablation that resulted in perforation and tamponade, from which there was survival.
Collapse
Affiliation(s)
- R J Hillock
- Department of Cardiology, Christchurch Hospital, New Zealand.
| | | | | |
Collapse
|
29
|
Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, Frampton C, Turner J, Crozier IG, Yandle TG. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003; 107:2786-92. [PMID: 12771003 DOI: 10.1161/01.cir.0000070953.76250.b9] [Citation(s) in RCA: 333] [Impact Index Per Article: 15.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND A recent landmark report has demonstrated that plasma B-type natriuretic peptide (BNP) measured in acute coronary syndromes independently predicts mortality, heart failure, and new myocardial infarction. After acute cardiac injury, left ventricular ejection fraction (LVEF) is also of prognostic significance and plays a major role in determining the therapeutic response. METHODS AND RESULTS The present report is the first from a substantial (n=666) cohort of patients with acute myocardial infarction to test the prognostic utility of concurrent measurements of BNP, amino-terminal BNP (N-BNP), norepinephrine, and radionuclide LVEF. The B-type peptides and LVEF were predictors of death, heart failure, and new myocardial infarction (all P<0.001) independent of patient age, gender, previous myocardial infarction, antecedent hypertension or diabetes, previous heart failure, plasma norepinephrine, creatinine, cholesterol, drug therapy, and coronary revascularization procedures. The combination of N-BNP (or BNP) with LVEF substantially improved risk stratification beyond that provided by either alone. Elevated N-BNP (or BNP) predicted new myocardial infarction only in patients with LVEF <40%. LVEF <40% coupled to N-BNP over the group median conferred substantial 3-year risks of death, heart failure, and new myocardial infarction of 37%, 18%, and 26%, respectively. N-BNP and BNP were equivalent prognostic markers for these clinical outcomes. CONCLUSIONS Plasma N-BNP (or BNP) and LVEF are complementary independent predictors of major adverse events on follow-up after myocardial infarction. Combined measurement provides risk stratification substantially better than that provided by either alone.
Collapse
Affiliation(s)
- A Mark Richards
- Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch, New Zealand.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Jardine DL, Melton IC, Crozier IG, English S, Bennett SI, Frampton CM, Ikram H. Decrease in cardiac output and muscle sympathetic activity during vasovagal syncope. Am J Physiol Heart Circ Physiol 2002; 282:H1804-9. [PMID: 11959646 DOI: 10.1152/ajpheart.00640.2001] [Citation(s) in RCA: 64] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The importance of cardiac output (CO) to blood pressure level during vasovagal syncope is unknown. We measured thermodilution CO, mean blood pressure (MBP), and leg muscle mean sympathetic nerve activity (MSNA) each minute during 60 degrees head-up tilt in 26 patients with recurrent syncope. Eight patients tolerated tilt (TT) for 45 min (mean age 60 +/- 5 yr) and 15 patients developed syncope during tilt (TS) (mean age 58 +/- 4 yr, mean tilt time 15.4 +/- 2 min). In TT patients, CO decreased during the first minute of tilt (from 3.2 +/- 0.2 to 2.5 +/- 0.3 l x min(-1) x m(-2), P = 0.001) and thereafter remained stable between 2.5 +/- 0.3 (P = 0.001) and 2.4 +/- 0.2 l x min(-1) x m(-2) (P = 0.004) at 5 and 45 min, respectively. In TS patients, CO decreased during the first minute (from 3.3 +/- 0.2 to 2.7 +/- 0.1 l x min(-1) x m(-2), P = 0.02) and was stable until 7 min before syncope, falling to 2.0 +/- 0.2 at syncope (P = 0.001). Regression slopes for CO versus time during tilt were -0.01 min(-1) in TT versus -0.1 l x min(-1) x m(-2) x min(-1) in TS (P = 0.001). However, MBP was more closely correlated to total peripheral resistance (R = 0.56, P = 0.001) and MSNA (R = 0.58, P = 0.001) than CO (R = 0.32, P = 0.001). In vasovagal reactions, a progressive decline in CO may contribute to hypotension some minutes before syncope occurs.
Collapse
Affiliation(s)
- D L Jardine
- Department of General Medicine, Christchurch Hospital, Christchurch, New Zealand.
| | | | | | | | | | | | | |
Collapse
|
31
|
Richards AM, Nicholls MG, Troughton RW, Lainchbury JG, Elliott J, Frampton C, Espiner EA, Crozier IG, Yandle TG, Turner J. Antecedent hypertension and heart failure after myocardial infarction. J Am Coll Cardiol 2002; 39:1182-8. [PMID: 11923044 DOI: 10.1016/s0735-1097(02)01737-0] [Citation(s) in RCA: 75] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVES We sought to assess the relationship of antecedent hypertension to neurohormones, ventricular remodeling and clinical heart failure (HF) after myocardial infarction (MI). BACKGROUND Heart failure is a probable contributor to the increased mortality observed after MI in those with antecedent hypertension. Hence, neurohormonal activation, adverse ventricular remodeling and a higher incidence of clinical HF may be expected in this group. However, no previous report has documented serial postinfarction neurohumoral status, serial left ventricular imaging and clinical outcomes over prolonged follow-up in a broad spectrum of patients with and without antecedent hypertension. METHODS Inpatient events were documented in 1,093 consecutive patients (436 hypertensive and 657 normotensive) with acute MI. In 68% (282 hypertensive, 465 normotensive) serial neurohormonal sampling and radionuclide ventriculography were performed one to four days and three to five months after infarction. Clinical outcomes were recorded over a mean follow-up of two years. RESULTS Plasma neurohormones were significantly higher in hypertensives than in normotensives one to four days and three to five months after infarction. From similar initial values, left ventricular volumes increased significantly in hypertensives, compared with normotensives. Left ventricular ejection fraction rose significantly in normotensive but not hypertensive patients. Together with higher inpatient (8.1% vs. 4.4%, p < 0.002) and post-discharge mortality (9.5% vs. 5.5%, p = 0.043), hypertensive patients incurred more inpatient HF (33% vs. 24%, p < 0.001) and more late HF requiring readmission to hospital (12.4% vs. 5.5%, p < 0.001). Antecedent hypertension predicted late HF in patients >64 years of age with neurohormonal activation and early left ventricular dilation. CONCLUSIONS Antecedent hypertension interacts with age, neurohumoral activation and early ventricular remodeling to confer greater risk of HF after MI.
Collapse
Affiliation(s)
- A Mark Richards
- Cardiology, Christchurch Hospital, Christchurch, New Zealand.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
|
33
|
Abstract
The mechanisms of action of omapatrilat, an agent that inhibits both neutral endopeptidase 24.11 and angiotensin-converting enzyme, on arterial function in patients with heart failure have not been previously reported. Forty-eight patients in New York Heart Association functional class II to III, left ventricular ejection fraction < or = 40%, and in sinus rhythm were randomized to a dose-ranging (2.5, 5, 10, 20, or 40 mg) study of omapatrilat for 12 weeks. Measurements were obtained at baseline and 12 weeks. Decreases in systolic (25.0 +/- 4.5 vs 2.8 +/- 5.0 mm Hg, p < 0.05) and mean arterial (13.9 +/- 3.0 vs 0.3 +/- 3.3 mm Hg, p < 0.05) pressure were seen after 12 weeks of therapy with higher doses. Ventricular-arterial coupling was improved with a dose-related decrease in augmentation index (-13.8 +/- 1.7% vs +6.1 +/- 2.1%, p < 0.01). There was no change in resting forearm blood flow between groups; however, maximum forearm vasodilator response during reactive hyperemia increased in the high-dose groups compared with the control group (+266 +/- 43% vs - 14 +/- 92%, p < 0.05). Omapatrilat induced an increase in postdose plasma atrial natriuretic peptide levels (30 +/- 11 vs -2 +/- 7 pmol/L, p < 0.01) in high-dose groups consistent with endopeptidase 24.11 inhibition. Omapatrilat shows beneficial changes in ventricular-vascular coupling and arterial function in heart failure.
Collapse
Affiliation(s)
- D R McClean
- Department of Cardiology, Christchurch Hospital, New Zealand
| | | | | | | |
Collapse
|
34
|
McClean DR, Ikram H, Garlick AH, Richards AM, Nicholls MG, Crozier IG. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. J Am Coll Cardiol 2000; 36:479-86. [PMID: 10933361 DOI: 10.1016/s0735-1097(00)00741-5] [Citation(s) in RCA: 87] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
OBJECTIVES We sought to examine the effects of long-term vasopeptidase inhibition in patients with heart failure. BACKGROUND The long-term effects of omapatrilat, an agent that inhibits both neutral endopeptidase and angiotensin-converting enzyme, on clinical status, neurohormonal indexes and left ventricular function in patients with chronic heart failure (CHF) have not been previously documented. METHODS Forty-eight patients in New York Heart Association functional class II or III, with left ventricular ejection fraction (LVEF)< or =40% and in sinus rhythm were randomized to a dose-ranging pilot study of omapatrilat for 12 weeks. Measurements were performed at baseline and 12 weeks. RESULTS There was an improvement in functional status, as reported by the patient (p<0.001) and physician (p<0.001) at 12 weeks. Dose-dependent improvements in LVEF (p<0.001) and LV end-systolic wall stress (sigma) (p<0.05) were seen, together with a reduction in systolic blood pressure (p<0.05). There was evidence of a natriuretic effect (p<0.001), and total blood volume decreased (p<0.05). Omapatrilat induced an increase in postdose plasma atrial natriuretic peptide levels (p<0.01) in the high dose groups, with a reduction in predose plasma brain natriuretic peptide (p<0.001) and epinephrine (p<0.01) levels after 12 weeks of therapy. Omapatrilat was well tolerated. CONCLUSIONS The sustained hemodynamic, neurohumoral and renal effects of omapatrilat, together with improved functional status, suggest that vasopeptidase inhibition has potential as a new therapeutic modality for the treatment of CHF.
Collapse
Affiliation(s)
- D R McClean
- Department of Cardiology, Christchurch Hospital, Christchurch, New Zealand
| | | | | | | | | | | |
Collapse
|
35
|
Jardine DL, Melton IC, Bennett SI, Crozier IG, Donaldson IM, Ikram H. Baroreceptor denervation presenting as part of a vagal mononeuropathy. Clin Auton Res 2000; 10:69-75. [PMID: 10823338 DOI: 10.1007/bf02279894] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
A 48-year-old woman presented with a history of progressive cough, dysphonia, dysphagia, and postural symptoms. Subsequent neurological investigations were consistent with a bilateral vagal mononeuropathy, and neurosarcoidosis was diagnosed after scalene node biopsy. Autonomic investigations including microneurography, neurohormones, and heart rate variability demonstrated arterial and cardiopulmonary baroreflex failure. In addition, parasympathetic control of heart rate was absent and consistent with a bilateral, nonselective lesion in the proximal vagus.
Collapse
Affiliation(s)
- D L Jardine
- Cardiology Department, Christchurch Hospital, New Zealand.
| | | | | | | | | | | |
Collapse
|
36
|
Richards AM, Nicholls MG, Yandle TG, Ikram H, Espiner EA, Turner JG, Buttimore RC, Lainchbury JG, Elliott JM, Frampton C, Crozier IG, Smyth DW. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. The Christchurch Cardioendocrine Research Group. Heart 1999; 81:114-20. [PMID: 9922344 PMCID: PMC1728940 DOI: 10.1136/hrt.81.2.114] [Citation(s) in RCA: 116] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
OBJECTIVE To determine the relations of plasma levels of brain natriuretic peptide (BNP), atrial natriuretic factor (ANF), N-terminal ANF (N-ANF), cyclic guanosine monophosphate (cGMP; the cardiac peptide second messenger), and plasma catecholamines to left ventricular function and to prognosis in patients admitted with acute myocardial infarction. DESIGN Plasma hormones and ventricular function (radionuclide ventriculography) were measured 1-4 days after myocardial infarction in 220 patients admitted to a single coronary care unit. Radionuclide scanning was repeated 3-5 months after infarction. Clinical events were recorded over a mean period of 14 months. RESULTS Both early and late left ventricular ejection fraction (LVEF) were most closely related to plasma BNP (r = -0.60, n = 220, p < 0.001; and r = -0.53, n = 192, p < 0.001, respectively), followed by ANF, N-ANF, cGMP, and the plasma catecholamines. Early plasma BNP concentrations less than twofold the upper limit of normal (20 pmol/l) had 100% negative predictive value for LVEF < 40% at 3-5 months after infarction. In multivariate analysis incorporating all the neurohormonal factors, only BNP remained independently predictive of LVEF < 40% (p < 0.005). Survival analysis by median levels of candidate predictors identified BNP as the most powerful discriminator for death (p < 0.0001). No early deaths (within 4 months) occurred in patients with plasma BNP concentrations below the group median (27 pmol/l), and over follow up only three of 26 deaths occurred in this subgroup. Of all episodes of left ventricular failure, 85% occurred in patients with plasma BNP above the median (p < 0.001). In multivariate analyses, BNP alone gave additional predictive information beyond sex, age, clinical history, LVEF, and plasma noradrenaline for both subsequent onset of LVF and death. CONCLUSIONS Plasma BNP measured within 1-4 days of acute myocardial infarction is a powerful independent predictor of left ventricular function, heart failure, or death over the subsequent 14 months, and superior to ANF, N-ANF, cGMP, and plasma catecholamines.
Collapse
Affiliation(s)
- A M Richards
- Department of Cardiology, Christchurch Hospital, PO Box 4345, Christchurch, New Zealand.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Abstract
In the pathophysiological study of vasovagal syncope, the nature of the interaction between baroreceptor sensitivity (BS), sympathetic withdrawal, and parasympathetic activity has yet to be ascertained. Altered BS may predispose toward abnormal sympathetic and parasympathetic responses to orthostasis, causing hypotension that may progress to syncope if there is sympathetic withdrawal. To examine this hypothesis, we monitored blood pressure (BP), heart rate (HR), BS, forearm blood flow, and muscle nerve sympathetic activity (MNSA) continuously in 18 vasovagal patients during 60 degrees head-up tilt, syncope, and recovery. Results were compared with those of 17 patients who were able to tolerate tilt for 45 min. During early tilt, BP was maintained in both groups by an increase in HR and MNSA from baseline (P < 0.01), but BS decreased more in the syncopal group (P < 0.05). At the start of presyncope (mean 2.7 +/- 0.2 min before syncope and 15.2 +/- 12 min after tilt), when BP fell, HR and sympathetic activity remained increased from baseline (P < 0.01). Thereafter, BP and HR correlated directly with sympathetic activity and regressed in linear fashion until syncope (P < 0.001), whereas BS increased to baseline. At syncope, BP, HR, and sympathetic activity fell below baseline (P < 0.01, P < 0.05, and P < 0.01, respectively), but BS did not increase. During recovery, sympathetic activity increased to baseline and BS increased (P < 0.05), whereas HR and BP remained low (P < 0.01 and P < 0.05, respectively). The mechanism for the initiation of hypotension during presyncope remains unknown, but BS may contribute. Vasodilatation and bradycardia during presyncope appear to be more closely related to withdrawal of sympathetic activity than to increased parasympathetic cardiac activity.
Collapse
Affiliation(s)
- D L Jardine
- Department of Cardiology, Christchurch Hospital, Christchurch, New Zealand
| | | | | | | | | | | |
Collapse
|
38
|
Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG, Buttimore RC, Lainchbury JG, Elliott JM, Ikram H, Crozier IG, Smyth DW. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998; 97:1921-9. [PMID: 9609085 DOI: 10.1161/01.cir.97.19.1921] [Citation(s) in RCA: 461] [Impact Index Per Article: 17.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
BACKGROUND Newly discovered circulating peptides, N-terminal pro-brain natriuretic peptide (N-BNP) and adrenomedullin (ADM), were examined for prediction of cardiac function and prognosis and compared with previously reported markers in 121 patients with myocardial infarction. METHODS AND RESULTS The association between radionuclide left ventricular ejection fraction (LVEF) and N-BNP at 2 to 4 days (r=-.63, P<.0001) and 3 to 5 months (r=-.58, P<.0001) after infarction was comparable to that for C-terminal BNP and far stronger than for ADM (r=-.26, P<.01), N-terminal atrial natriuretic peptide (N-ANP), C-terminal ANP, cGMP, or plasma catecholamine concentrations. For prediction of death over 24 months of follow-up, an early postinfarction N-BNP level > or = 160 pmol/L had sensitivity, specificity, positive predictive value, and negative predictive values of 91%, 72%, 39%, and 97%, respectively, and was superior to any other neurohormone measured and to LVEF. Only 1 of 21 deaths occurred in a patient with an N-BNP level below the group median (Kaplan-Meier survival analysis, P<.00001). For prediction of heart failure (left ventricular failure), plasma N-BNP > or = 145 pmol/L had sensitivity (85%) and negative predictive value (91%) comparable to the other cardiac peptides and was superior to ADM, plasma catecholamines, and LVEF. By multivariate analysis, N-BNP but not ADM provided predictive information for death and left ventricular failure independent of patient age, sex, LVEF, levels of other hormones, and previous history of heart failure, myocardial infarction, hypertension, or diabetes. CONCLUSIONS Plasma N-BNP measured 2 to 4 days after myocardial infarction independently predicted left ventricular function and 2-year survival. Stratification of patients into low- and high-risk groups can be facilitated by plasma N-BNP or BNP measurements, and one of these could reasonably be included in the routine clinical workup of patients after myocardial infarction.
Collapse
Affiliation(s)
- A M Richards
- Department of Cardiology, Christchurch Hospital, Christchurch School of Medicine, New Zealand
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Affiliation(s)
- M G Nicholls
- Department of Medicine, Christchurch Hospital, New Zealand
| | | | | | | |
Collapse
|
40
|
Abstract
In a controlled study, 26 patients with a history of recurrent syncope were found to have increased arginine vasopressin, corticotrophin, and atrial natriuretic factor levels after 5 minutes of 60 degrees head-up tilt, long before they became hypotensive. The exaggerated neurohormonal response in these patients may indicate a greater sensitivity to central hypovolemia which may predispose to vasovagal syncope, mediated by the vasodilatory effects of atrial natriuretic factor or the sensitization of mechanoreceptors by arginine vasopressin.
Collapse
Affiliation(s)
- D L Jardine
- Cardiology Department, Christchurch Hospital, New Zealand
| | | | | | | | | | | |
Collapse
|
41
|
Abstract
A 30 year old woman with a lifelong history of severe, recurrent, vasovagal syncope became asystolic for 30 seconds after 37 minutes of 60 degrees head-up tilt. During early tilt, sympathetic activity, heart rate, left ventricular contractility, and cardiac output increased. Mean blood pressure was initially maintained. Presyncope was associated with maximal contractility and bradycardia despite sustained sympathetic activity. Subsequently, asystole occurred associated with complete withdrawal of muscle nerve sympathetic activity. In asystolic vasovagal reactions, presyncope may be triggered by increased left ventricular contractility and is associated with increased levels of parasympathetic and sympathetic activity. Asystole and peripheral vasodilatation may be caused by sudden and complete withdrawal of the increased sympathetic activity.
Collapse
Affiliation(s)
- D L Jardine
- Department of Cardiology, Christchurch Hospital, New Zealand
| | | | | |
Collapse
|
42
|
Florkowski CM, Crozier IG, Nightingale S, Evans MJ, Ellis MJ, Joyce P, Donald RA. Plasma cortisol, PRL, ACTH, AVP and corticotrophin releasing hormone responses to direct current cardioversion and electroconvulsive therapy. Clin Endocrinol (Oxf) 1996; 44:163-8. [PMID: 8849570 DOI: 10.1046/j.1365-2265.1996.642464.x] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
OBJECTIVE We aimed to evaluate and contrast the hypothalamo-pituitary-adrenal (HPA) response to direct current (DC) cardioversion and electroconvulsive therapy (ECT). SUBJECTS Six male subjects (mean age 61.2 years, range 46-74) with chronic atrial fibrillation were selected for cardioversion. Six subjects with depression (one male, five female; mean age 43.2 years, range 31-59) were selected for ECT. Those taking glucocorticoid drugs, opiates or beta-adrenoceptor antagonists were excluded. MEASUREMENTS Patients attended for serial blood sampling on the day of cardioversion or ECT, and for an equivalent time period on a control day at least one week before. Intravenous propofol was given to each subject for anaesthesia on the day of cardioversion or ECT. On both study and control days, blood samples were taken at -30, -15, 0 (just prior to cardioversion or ECT), +5, +10, +15, +30, +60, +90 and +120 minutes for assay of cortisol, PRL, ACTH, AVP and CRH. RESULTS For cardioversion: plasma cortisol increased from 252.5 +/- 39.8 to a maximum of 721.3 +/- 50 nmol/l at 30 minutes (P < 0.0001 compared with control day). ACTH increased from 12.8 +/- 2.8 to a maximum of 64 +/- 14 pmol/l at 5 minutes (P < 0.0001 compared with control day). AVP increased from 6.6 +/- 3.3 to a maximum of 42.9 +/- 16 pmol/l at 5 minutes post-cardioversion (P < 0.005 compared with control day). PRL increased from 141 +/- 28 mlU/l to a maximum of 873 +/- 219 mlU/l at 10 minutes (P < 0.001 compared with control day). There was no significant difference in CRH responses between cardioversion and control days. There was no significant correlation between total electrical energy delivered and maximum ACTH and AVP responses (R = 0.54 and -0.13, respectively). For ECT: on the day of ECT plasma cortisol increased from 419.5 +/- 25.9 to a maximum of 614.7 +/- 26.9 nmol/l (P < 0.002 compared with control day). ACTH increased from 22.7 +/- 6.2 to a maximum of 77.8 +/- 19.1 pmol/l (P < 0.0003 compared with control day). PRL increased from 771 +/- 317 to a maximum of 3152 +/- 703 mlU/l (P < 0.001 compared with control day, and significantly greater than the peak response to cardioversion, P < 0.03). AVP increased from 13.0 +/- 10.8 to a maximum of 35.1 +/- 5.6 pmol/l (P < 0.02 compared with control day). There was no significant difference in CRH responses between ECT and control days. Peak cortisol and ACTH responses did not differ significantly between ECT and cardioversion. Baseline cortisol levels, however, were significantly higher in the depressed group compared with the cardioversion group, P < 0.02, but not ACTH or AVP. CONCLUSION Significant hypothalamic-pituitary-adrenal activation and PRL release occur in response to both cardioversion and ECT. AVP may have an important role in mediating the acute ACTH response to electrical stimulation.
Collapse
Affiliation(s)
- C M Florkowski
- Department of Endocrinology, Christchurch Hospital, New Zealand
| | | | | | | | | | | | | |
Collapse
|
43
|
Ikram H, Foy SG, Low CJ, Redfern SA, Shirlaw TM, Bennett SI, Crozier IG. Hemodynamic comparison of dopexamine and nitroprusside at high and low doses in patients with coronary artery disease and impaired left ventricular function. J Cardiovasc Pharmacol 1995; 26:777-83. [PMID: 8637193 DOI: 10.1097/00005344-199511000-00015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Pure vasodilator drugs are currently the preferred agents for treatment of acute and chronic heart failure of all grades of severity. In contrast, the role of drugs that combine vasodilation with inotropic action remains highly controversial despite their several advantageous physiological actions and long therapeutic history in heart failure. We hypothesize that this uncertainty might be due first to subtle unfavorable hemodynamic effects not detectable by the relatively crude hemodynamic methods by which these agents are usually analyzed, particularly with regard to the quantification of afterload, and secondly to the narrow therapeutic range of these drugs, such that the dose administered is critical. We tested this hypothesis by comparing several refined hemodynamic measurements of dopexamine, an inotropic vasodilator, with a pure arteriovenous dilator (sodium nitroprusside, SNP) on left ventricular (LV) systolic and diastolic function, large arterial behavior, and coupling of the left ventricle to the arterial system at two dose levels in 35 patients with ischemic heart disease. The study protocol was a fixed order of 15-min infusions of saline, dopexamine 1 microg/kg/min, and dopexamine 3 + ++microg/kg/min, or saline, SNP 1 microg/kg/min, and SNP 3 microg/kg/min. Detailed hemodynamic observations were made at the end of each 15-min infusion period. Both drugs produced equivalent arterial vasodilation, as measured by the decrease in systemic vascular resistance index (SVRI), but dopexamine resulted in a significantly greater increase in cardiac index (CI). Myocardial contractility, assessed by several load-independent indexes, increased with dopexamine, as anticipated with an inotropic drug, but did not alter with SNP. Arterial compliance, a measure of the distensibility of large conduit arteries, was increased by SNP but not by dopexamine. Arterial wave reflection was increased by dopexamine, especially at high doses, but reduced by SNP. Increased arterial compliance and reduced wave reflection reduce LV afterload. SNP reduced preload, whereas dopexamine had no effect on this aspect of ventricular function. Vasodilator drugs and those which combine vasodilator and inotropy increase cardiac output (CO) and reduce SVR. Therapy with inotropic vasodilators has no effect on preload and does not reduce the dynamic components of ventricular afterload, although it does reduce its static components. These effects are dose dependent; there is less perturbation of afterload at lower doses. In contrast, vasodilator therapy reduces preload and both static and dynamic parts of afterload.
Collapse
Affiliation(s)
- H Ikram
- Department of Cardiology, Christchurch Hospital, New Zealand
| | | | | | | | | | | | | |
Collapse
|
44
|
Foy SG, Crozier IG, Richards AM, Nicholls MG, Turner JG, Frampton CM, Ikram H. Neurohormonal changes after acute myocardial infarction. Relationships with haemodynamic indices and effects of ACE inhibition. Eur Heart J 1995; 16:770-8. [PMID: 7588920 DOI: 10.1093/oxfordjournals.eurheartj.a060995] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
To determine the neurohormonal response to angiotensin-converting enzyme (ACE) inhibition after acute myocardial infarction, 36 patients presenting within 6 h of the onset of chest pain were studied in a single regional cardiology service. In this double-blind study, 13 patients were randomized to receive captopril, 12 patients received enalapril, and 11 patients received placebo, for 12 months. In patients receiving placebo, acute myocardial infarction was associated with activation of the renin-angiotensin-aldosterone and sympathetic nervous systems, and stimulation of plasma brain natriuretic peptide and atrial natriuretic peptide levels. ACE inhibition did not significantly alter circulating levels of norepinephrine, brain natriuretic peptide or atrial natriuretic peptide. Compared with placebo, enalapril induced a steep decline in plasma ACE activity, and plasma angiotensin II levels were reduced by both ACE inhibitors. Using grouped data, circulating levels of brain natriuretic peptide at the zero sampling time were significantly higher than atrial natriuretic peptide values. Brain natriuretic peptide levels at 72 h were significantly correlated with the radionuclide left ventricular ejection fraction measured 5 days and 3 months after infarction. Similar associations were observed for atrial natriuretic peptide and norepinephrine. We confirm activation of the renin-angiotensin-aldosterone and sympathetic nervous systems after acute myocardial infarction. The atrial natriuretic peptide and brain natriuretic peptide and sympathetic nervous system responses to acute myocardial infarction were not significantly modified by ACE inhibition. Brain natriuretic peptide and atrial natriuretic peptide levels were significantly correlated with the left ventricular ejection fraction measured 5 days and again 3 months after myocardial infarction, and may prove a useful prognostic index.
Collapse
Affiliation(s)
- S G Foy
- Department of Cardiology, Christchurch Hospital, New Zealand
| | | | | | | | | | | | | |
Collapse
|
45
|
Crozier IG, Elliott JM, Ikram H, Nicholls MG, Richards AM, Smyth D. Core services and cardiac surgery. N Z Med J 1995; 108:133. [PMID: 7739824] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
|
46
|
Nicholls MG, Charles CJ, Crozier IG, Espiner EA, Ikram H, Rademaker MJ, Richards AM, Yandle TG. Blockade of the renin-angiotensin system. J Hypertens Suppl 1994; 12:S95-103. [PMID: 7769497] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
HISTORICAL OVERVIEW Milestones in understanding the renin-angiotensin system (RAS) until the development of angiotensin II antagonists are described briefly. Sites at which the RAS might be blocked are outlined. PEPTIDE ANALOGUE ANTAGONISTS OF ANGIOTENSIN II RECEPTORS Saralasin-like compounds were used in numerous experimental and clinical situations and clarified the role of the RAS. Some of these situations are described (e.g. hypertension and cardiac failure) particularly in regard to the control of arterial pressure and aldosterone secretion by the RAS. Saralasin and its analogues allowed visualization, for the first time, of complete angiotensin II/effector (especially blood pressure) dose-response curves. ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS The clinical usefulness of ACE inhibitors in hypertension, cardiac failure, diabetes mellitus and after acute myocardial infarction is emphasized. In particular, ACE inhibitors have actions beyond blockade of angiotensin II formation, necessitating cautious interpretation of data from their use. RENIN INHIBITORS Experience with renin inhibitors in documenting and confirming the role of the RAS is outlined. NON-PEPTIDE ANGIOTENSIN II RECEPTOR ANTAGONISTS: Characteristics of losartan-like compounds are discussed in brief, and the results of their limited use in clinical medicine are outlined. CONCLUSION Blocking agents have led to great advances in knowledge of the RAS and its physiological and pathophysiological functions. ACE inhibitors are used regularly in a number of clinical disorders and, in theory, have therapeutic potential beyond alternative antihypertensive drugs in the prevention of cardiovascular complications in essential hypertension. The place of renin inhibitors and angiotensin II receptor antagonists in clinical practice, however, remains to be determined.
Collapse
Affiliation(s)
- M G Nicholls
- Department of Medicine, Christchurch Hospital, New Zealand
| | | | | | | | | | | | | | | |
Collapse
|
47
|
Affiliation(s)
- A M Richards
- Department of Medicine and Cardiology, Princess Margaret Hospital, Christchurch, New Zealand
| | | | | |
Collapse
|
48
|
Foy SG, Crozier IG, Turner JG, Richards AM, Frampton CM, Nicholls MG, Ikram H. Comparison of enalapril versus captopril on left ventricular function and survival three months after acute myocardial infarction (the "PRACTICAL" study). Am J Cardiol 1994; 73:1180-6. [PMID: 8203335 DOI: 10.1016/0002-9149(94)90178-3] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Left ventricular (LV) function and survival can be improved with captopril when initiated later than 24 hours after acute myocardial infarction. Animal studies suggest additional benefits may be obtained with earlier initiation of angiotensin-converting enzyme (ACE) inhibitors. The effects on LV function of captopril and enalapril initiated within 24 hours of myocardial infarction were studied. Two hundred twenty-five patients with acute myocardial infarction were enrolled within 24 hours of the onset of chest pain. They were randomized to receive either captopril 25 mg three times daily, enalapril 5 mg three times daily, or placebo. LV ejection fraction (EF) and volumes were measured by radionuclide ventriculography at baseline during treatment and at 3 months after a 3-day withdrawal from therapy. The ACE inhibitor group had a significant increase in EF (45 +/- 1 to 47 +/- 1%; p = 0.005) and significantly attenuated LV dilatation compared with results in the placebo group (175 +/- 6 to 189 +/- 7 ml in the placebo group vs 168 +/- 4 to 172 +/- 4 ml in the ACE inhibitor group; p = 0.051 for LV end-diastolic volume; and 99 +/- 6 to 108 +/- 7 ml in the placebo group vs 94 +/- 3 to 94 +/- 4 ml; p = 0.026 for LV end-systolic volume). The beneficial effects of ACE inhibitor therapy on LV function were observed irrespective of the degree of initial LV dysfunction and were comparable in both the captopril and enalapril groups.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- S G Foy
- Department of Cardiology, Princess Margaret Hospital, Christchurch, New Zealand
| | | | | | | | | | | | | |
Collapse
|
49
|
Donald RA, Crozier IG, Foy SG, Richards AM, Livesey JH, Ellis MJ, Mattioli L, Ikram H. Plasma corticotrophin releasing hormone, vasopressin, ACTH and cortisol responses to acute myocardial infarction. Clin Endocrinol (Oxf) 1994; 40:499-504. [PMID: 8187316 DOI: 10.1111/j.1365-2265.1994.tb02489.x] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
OBJECTIVES We assessed the magnitude and duration of the response of hypothalamic-pituitary-adrenal hormones to the stress of myocardial infarction, in the presence and absence of angiotensin converting enzyme inhibitors. In particular, we wished to analyse the interrelationships between peripheral plasma levels of corticotrophin releasing hormone (CRH), vasopressin (AVP) and adrenocorticotrophin (ACTH), and also between ACTH and cortisol, during a prolonged medical stress. DESIGN All hormones were measured within 6 hours of the onset of an acute myocardial infarction. Patients were randomly allocated to three different study groups according to a double blind procedure. PATIENTS Group 1 (10 patients) received placebo treatment, Group 2 (13 patients) received a maintenance dose of captopril 25 mg three times daily, Group 3 (11 patients) received enalapril 5 mg three times daily. MEASUREMENTS Peptide hormones were measured by radioimmunoassay, and cortisol by ELISA. Reference ranges for all hormones were obtained from 40 or more volunteers from the electoral roll. RESULTS At the start of the study, mean +/- SEM plasma AVP (27.9 +/- 4.6 pmol/l) was significantly (P < 0.001) raised above the mean for the reference range (1.82 +/- 0.09 pmol/l), and 12 patients had values > 50 pmol/l. Mean plasma cortisol (960 +/- 89.6 nmol/l) was also raised above the reference range mean (554 +/- 28 nmol/l, P < 0.001), as was mean plasma CRH (4.97 +/- 0.5 pmol/l, reference mean 1.52 +/- 0.09 pmol/l, P < 0.001). By contrast, mean ACTH (3.88 +/- 0.66 pmol/l) was significantly less than the reference mean (10.7 +/- 0.7 pmol/l, P < 0.001). During the 72-hour observation period there was a highly significant fall (P < 0.001) in plasma CRH, AVP and cortisol. By contrast, plasma ACTH rose, and the change with time of ACTH was significantly different from the fall in plasma CRH, AVP or cortisol (P < 0.001 for each comparison). No significant differences in plasma CRH, AVP, ACTH or cortisol responses to placebo, captopril or enalapril were observed. CONCLUSIONS Within 6 hours of a myocardial infarction, mean plasma CRH, AVP and cortisol values were very significantly raised above mean control values, while ACTH was very significantly reduced. During the 3 days following an acute myocardial infarction, plasma CRH, AVP and cortisol fell substantially, and this pattern was not influenced by angiotensin converting enzyme inhibitors. By contrast, plasma ACTH showed a significant increase with time. This suggests that the usual relationships between CRH, AVP and ACTH, and between ACTH and cortisol are disturbed in patients admitted to hospital with myocardial infarction. Maximum levels of AVP observed in 12 patients exceeded 50 pmol/l, which may be sufficiently high to interfere with tissue perfusion. It is postulated that V1 AVP receptor antagonists may have a therapeutic application in limiting infarct size.
Collapse
Affiliation(s)
- R A Donald
- Department of Cardiology, Princess Margaret Hospital, Christchurch, New Zealand
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Ikram H, Low CJ, Shirlaw TM, Foy SG, Crozier IG, Richards AM, Khurmi NS, Horsburgh RJ. Angiotensin converting enzyme inhibition in chronic stable angina: effects on myocardial ischaemia and comparison with nifedipine. Heart 1994; 71:30-3. [PMID: 8297690 PMCID: PMC483605 DOI: 10.1136/hrt.71.1.30] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
OBJECTIVES To determine the anti-ischaemic effects of a new angiotensin converting enzyme inhibitor, benazepril, compared with nifedipine, alone and in combination, in chronic stable angina caused by coronary artery disease. DESIGN Placebo controlled, double blind, latin square design. SETTING Regional cardiology service for a mixed urban and rural population. SUBJECTS 40 patients with stable exertional angina producing at least 1 mm ST segment depression on exercise test with the Bruce protocol. 34 patients completed all four phases of the trial. INTERVENTIONS Each patient was treated with placebo, benazepril (10 mg twice daily), nifedipine retard (20 mg twice daily), and a combination of benazepril and nifedipine in the same doses, in random order for periods of two weeks. MAIN OUTCOME MEASURES AND RESULTS Total duration of exercise was not increased by any treatment. Exercise time to the development of 1 mm ST segment depression was not significantly changed with benazepril alone or in combination with nifedipine but was increased with nifedipine from 4.18 (1.8) min to 4.99 (1.6) min (95% confidence interval (95% CI) 0.28 to 1.34; p < 0.05). There was a significant relation between increase in duration of exercise and resting renin concentration (r = 0.498; p < 0.01). Myocardial ischaemia during daily activity, as assessed by ambulatory electrocardiographic monitoring, was reduced by benazepril and by the benazepril and nifedipine combination. This was significant for total ischaemic burden (451(628) min v 231(408) min; 95% CI -398 to -41 min; p < 0.05) and maximal depth of ST segment depression (-2.47(1.2) mm v -2.16 mm; 95% CI 0.04 to 0.57; p < 0.05) for the combination and for maximal ST segment depth for benazepril monotherapy (-2.47 (1.2) mm v -1.96(1.2) mm; 95% CI 0.18 to 0.91; p < 0.05). Benazepril significantly altered the circadian rhythm of cardiac ischaemia, abolishing the peak ischaemic periods at 0700 to 1200 and 1700 to 2300 (p < 0.05). CONCLUSIONS Benazepril, an angiotensin converting enzyme inhibitor, had a modest anti-ischaemic effect in effort angina, but this effect was not as pronounced as with nifedipine. The anti-ischaemic action was more noticeable in asymptomatic ischaemia during daily activity, whereas nifedipine had little effect on this aspect of myocardial ischaemia. The combination of benazepril and nifedipine reduced ischaemia of daily activity.
Collapse
Affiliation(s)
- H Ikram
- Department of Cardiology, Princess Margaret Hospital, Christchurch, New Zealand
| | | | | | | | | | | | | | | |
Collapse
|